A 70-year-old with type 2 diabetes and PAD asks about SGLT2 inhibitors' benefits beyond glucose control. Which is accurate?...

Question

A 70-year-old with type 2 diabetes and PAD asks about SGLT2 inhibitors' benefits beyond glucose control. Which is accurate?

Accepted Answer

SGLT2 inhibitors reduce CKD progression and CV events in CKD with albuminuria

Answer

SGLT2 inhibitors have no renal benefit

Answer

SGLT2 inhibitors are contraindicated in CKD

Answer

Only GLP-1 receptor agonists reduce kidney outcomes

Answer

Benefits are limited to eGFR >90

us-abim MCQ (SBA): CKD Risk Reduction